An important goal of this study is to evaluate the length of time cancer is not growing or spreading in participants when treated with zanzalintinib compared to everolimus. In addition, this study will also evaluate if zanzalintinib can shrink tumors and help participants live longer as compared to everolimus. This information will help researchers learn if zanzalintinib can be used to treat neuroendocrine cancer.

Do you or your child have a kidney condition and take certain meds? Join our study and help us make a difference! You'll also get paid for your time.

Do you have protein in your urine and have had a kidney biopsy? You may be able to participate in a research study to test to see if a study drug can reduce the amount of protein in your urine.

Have you had an alcoholic drink today or in the past 4 months? Have you been diagnosed with alcohol-related liver disease (ALD)? You may be able to participate in a research study that is exploring a medication that may help reduce the effects of ALD. Compensation provided.

If you have protein in the urine and African descent, Hispanic or American Indian you might have a gene call APOL1 contributing kidney disease. This study will test if you have change in the gene. If you do have that change you can participate in this study .

Do you have lupus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM)? You may be eligible for a new CAR-T therapy conducted at University of North Carolina at Chapel Hill. Please reach out to learn more about this new innovative treatment.

Have you been diagnosed with Hepatocellular Carcinoma (HCC), also referred to as Liver Cancer? If so, you may be a good fit for a clinical trial to evaluate how 3 drugs work in combination, and which dose is the best to treat your disease. The 3 drugs are casdozokitug (casdozo-key-tug), toripalimab (tor-i-pal-i- mab) and bevacizumab (bev-uh-siz-oo-mab).

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with Compensated Cirrhosis due to NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

The purpose of this study is to find out whether the addition of HDV to Humalog® will improve diabetes control by reducing high blood sugar after meals and/or reducing the risk of low blood sugar (hypoglycemia) during insulin treatment. The safety and tolerability of Humalog® with or without added HDV will also be evaluated. The study drugs will be administered by subcutaneous (under the skin) injection.

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).